At Decibel, we are exclusively focused on discovering and developing transformative treatments to restore and improve hearing and balance. We have assembled a highly experienced scientific team and built a unique platform to achieve this goal.
Entrepreneurs who have raised more than $5.5 billion in capital and successfully executed 4 IPOs
Scientists working at the cutting edge of inner ear biology, genetics and genomics, bioinformatics, gene therapy, and drug delivery
Drug developers with deep expertise in pharmacology, translational medicine, and manufacturing, who have filed more than 45 INDs and launched 17 therapies
Clinicians who have spent years treating hearing and balance disorders and are applying their expertise to clinical development
Entrepreneurs who have raised more than $5.5 billion in capital and successfully executed 4 IPOs
Bridget Cleff, MBA
Vice President, New Product Planning and Corporate Strategy
Bridget Cleff joined Decibel in April 2021 and brings over 20 years of expertise in strategy, new product planning, business development, marketing, and commercial operations in the life sciences industry. Bridget’s experience has focused on collaborating with R&D on pipeline programs and leading cross-functional strategies to bring innovative treatments to market to address patients’ unmet needs. She has a proven record of commercial pipeline planning from pre-clinical through launch across multiple therapeutic areas, including genetic diseases. Prior to Decibel, Bridget was Commercial Development Leader for the CNS gene therapy portfolio at Spark Therapeutics (acquired by Roche). Before Spark, Bridget was Vice President, New Products Commercial Strategy at Aevi Genomic Medicine, overseeing global commercial plans for the portfolio. Prior to Aevi, Bridget spent nine years at Takeda/Shire Pharmaceuticals, where she held roles of increasing responsibility, including commercial assessment for business development, marketing, and global market research.
In earlier roles, Bridget worked in strategic product development and operations management at Takeda Oncology/Millenium Pharmaceuticals, strategy consulting at The Wilkerson Group and as a health economics researcher at the Leonard Davis Institute of Health Economics, University of Pennsylvania.
Bridget earned an MBA in entrepreneurial management and health care management from The Wharton School of the University of Pennsylvania and a BA in economics from Bucknell University.
Elaine Cope, MBA
Vice President, Operations
Elaine Cope joined Decibel in September 2017 and has over 20 years of experience in life sciences, including space planning, operations management and compliance. Her role at Decibel includes program management, real estate and facilities operations, business continuity, security, daily facilities and lab operations management, and all EH&S activity and initiatives.
Prior to Decibel, Elaine worked at Infinity Pharmaceuticals for over fifteen years, where she held multiple roles of increasing responsibility in the areas of lab operations, facilities and real estate. Elaine holds a Master of Philosophy in chemistry from the University of Manchester, England and a Bachelor’s degree in natural sciences from Trinity College Dublin, Ireland.
Geoff Horwitz, Ph.D.
Vice President, Corporate Development and Head of Business Development
Geoff joined Decibel in the fall of 2017 and brings over 10 years of company building experience and over 12 years of experience in the otology field. At Decibel, he leads business development and various corporate development activities including corporate communications and alliance management. Prior to joining Decibel, Geoff was part of the core venture creation team at PureTech Health, a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. During his time at PureTech, Geoff led external sourcing, helped take the parent company public in London and co-founded Sonde Health, a health technology company with a voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. Prior to PureTech, Geoff worked in business development and strategic initiatives at Boston Children’s Hospital. Geoff received his BS degree from Trinity University and his PhD in neuroscience from the University of Virginia.
Elaine Kernbauer, MS
Vice President Development Operations
Elaine’s career in research has been focused primarily on rare pediatric drug development. Prior to joining Decibel in 2022, Elaine held operational leadership roles at multiple biotech organizations involving early & late-stage assets, most recently at Taysha Gene Therapies and Novartis Gene Therapies (formerly AveXis). Elaine has been involved in multiple product approvals for rare, pediatric indications, including the global approvals of Zolgensma®, a gene therapy for spinal muscular atrophy. Elaine received her BS degree from the University of Illinois Urbana Champaign and her MS degree from Northwestern University.
Executive Vice President, Chief Development Officer
John Lee joined Decibel in September 2016 as senior vice president of pharmaceutical development and brings over 20 years of experience in the biotechnology industry. Prior to Decibel, he served as senior vice president of pharmaceutical development at Infinity Pharmaceuticals. Throughout his 15 years at Infinity, John held roles of increasing responsibility and leadership. Most recently, he was responsible for chemistry manufacturing and control (CMC), analytical sciences, formulation sciences and clinical supply and distribution for the company’s drug candidates across all phases of global clinical development. He was also co-chair of Infinity’s operational leadership team. Previously, John was a new product manager at Corning Life Sciences, where he was responsible for developing new life science products. Before Corning, John was an early member of Millennium Pharmaceuticals and played a key role in the successful positional cloning of the mouse obesity gene tubby, before becoming project lead for an ovarian cancer diagnostic program. Prior to Millennium, John worked in the developmental chronobiology lab of Steven Reppert at Massachusetts General Hospital, where he focused on cloning G-protein coupled receptors and circadian biology. John received his bachelor’s degree in materials science and engineering from the Massachusetts Institute of Technology.
Laurence Reid, Ph.D.
President and Chief Executive Officer
Laurence joined Decibel in January 2020. He previously served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery and development opportunities. Before that, Laurence was CEO of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018. Prior to that, he was the senior vice president and chief business officer of Alnylam Pharmaceuticals, where he was responsible for the company’s business development, finance and legal functions. Before coming to Alnylam, Laurence was the chief business officer at Ensemble Discovery, where he led the company’s strategic planning and corporate development efforts. Laurence previously spent ten years at Millennium Pharmaceuticals in a range of general management and business development positions. In addition to his professional interests, Laurence is a board member of the Possible Project, a board member of Garuda Therapeutics and board advisor to Life Science Cares. He earned his Ph.D. from King’s College London and his B.A. from Cambridge University.
Vice President, Program Management, Strategy and Operations
Courtney brings 20+ years of experience in the biotechnology setting and has devoted much of her professional life to developing therapies for rare genetic diseases. Courtney’s breadth of portfolio support includes novel small molecules, antisense oligonucleotides and biologic programs, across many therapeutic areas and at all stages of development.
Previously, she was Senior Director of research and development for Solid Biosciences and held a leadership role in advancing gene therapy candidates into clinical development for Duchenne Muscular Dystrophy, led the development of primary clinical biomarkers, and was responsible for overseeing development strategies for all nonclinical programs.
Prior to Solid, Courtney spent five years at Sarepta Therapeutics, co-leading a team whose innovative work was paramount to EXONDYS 51 regulatory filing that gained an unprecedented, accelerated approval and paved the way for subsequent approvals for VYONDYS53 and AMONDYS45 in patients with high unmet medical needs. Prior to Sarepta, Courtney held positions of increasing responsibility at Infinity Pharmaceuticals. While at Infinity, Courtney was a recognized leader in nonclinical development of novel small molecules targeting chronic and neuropathic pain and became highly skilled at building and managing external collaborations with diverse stakeholders.
Adrian M Timmers, Ph.D.
Vice President, Research and Platform
Adrian Timmers joined Decibel Therapeutics in April 2023. He has over 20 years of experience in developing and testing AAV gene therapies focusing on retinal, liver, CNS, ear and RPE. During his tenure at University of Florida, his initial focus was towards developmental retinal gene expression and inherited retinal diseases followed by AAV gene therapy. At Alcon, a subsidiary of Novartis, he worked on anti VEGF siRNA therapeutics and the screening of antivirals for corneal viral infections. When he joined AGTC, his team continued the work on IRD’s ranging from color blindness, AMD and retinitis pigmentosa followed by expansion of the AAV gene therapy portfolio into CNS and ear. Prior to Decibel Therapeutics, he was at Editas Medicine exploring genome editing technologies for IRD’s, glaucoma and liver.
Adrian came to the US from the Netherlands where he had earned his PhD in Biochemistry from the Radboud University, beginning his postdoctoral academic career at the University of Florida advancing into a tenure track position. He left academia for a career in the pharmaceutical industry leading to a continuation of AAV gene therapy research and development in the biotech hub of Boston/Cambridge where he led and managed several Research and Development, and Preclinical Research groups.
Anna Trask, MA
Executive Vice President, Chief People Officer
Anna Trask joined Decibel as chief people, community and culture officer in January 2018, bringing with her nearly 30 years of experience in the field of human resources. Prior to Decibel, Anna served as senior director, human resources at the Dana-Farber Cancer Institute, as chief human resource officer at Boston Medical Center Healthnet Plan and in leadership positions at Neighborhood Health Plan, Pine Manor College and Harvard Pilgrim Health Care/Harvard Community Health Plan. Across these roles, she was responsible for creating and implementing innovative organizational design and development programs to improve critical areas such as transparency, efficiency and effectiveness; professional development and organizational diversity. Anna graduated with a B.A. in politics from Mount Holyoke College and has a master’s degree in psychology from Boston University.
Vassili Valayannopoulos, M.D., Ph.D., MBA
Vice President, Head of Clinical Research and Development
Dr. Valayannopoulos, M.D., Ph.D., MBA, is a Rare Disease expert and an experienced pharma industry executive. He has previously served in Clinical Development and Medical Affairs leadership roles at Ultragenyx Pharmaceuticals and at Sanofi Genzyme supporting Rare Disease drug development and medical lifecycle management. With training in pediatric metabolic medicine, clinical genetics and pediatric neurology and prior to joining the pharma industry, he served as Senior Faculty and Principal Investigator at the Department of Pediatric Metabolic Disorders and Pediatric Neurology at Necker-Enfants Malades University Hospital, Paris, France. Dr. Valayannopoulos conducted clinical research in collaboration with Institut IMAGINE at Necker with a special focus on neurodegenerative metabolic diseases, gene therapy and lysosomal storage disorders, and worked with expert networks for inherited Metabolic disorders (E-IMD, CETL). He has served as Principal Investigator and coordinator in several clinical trials (academic and industry sponsored) and is an author or co-author on numerous peer-reviewed journal articles. Dr. Valayannopoulos earned his medical degree and completed his pediatric residency program at Paul Sabatier University Medical School in Toulouse, France and has received a Master’s degree in Genetics, a PhD in Molecular Biology, both from Paris Descartes University and his MBA from MIT Sloan School of Management.
Board of Directors
Scientific Advisory Board
We actively seek additional partnerships and in-licensing opportunities. If you would like to discuss an opportunity with Decibel, please contact Licensing@decibeltx.com